Jefferies Group Reiterates “Positive” Rating for Amarin Co. plc (AMRN)
Amarin Co. plc (NASDAQ:AMRN)‘s stock had its “positive” rating reaffirmed by Jefferies Group in a research note issued on Thursday, StockRatingsNetwork.com reports.
The analysts wrote, “We outline several reasons why we remain positive on near term approval prospects for the Vascepa ANCHOR indication in advance of the advisory committee meeting set for October 16 and the expected release of the FDA’s briefing documents on Friday (October 11). The ANCHOR Indication of mixed dyslipidemia is critical for long-term Vascepa sales growth and we view it as central to our AMRN Buy thesis.”
AMRN has been the subject of a number of other recent research reports. Analysts at Goldman Sachs Group Inc. raised their price target on shares of Amarin Co. plc from $3.00 to $9.00 in a research note to investors on Wednesday. They now have a “neutral” rating on the stock. Finally, analysts at JPMorgan Chase & Co. cut their price target on shares of Amarin Co. plc from $12.00 to $11.00 in a research note to investors on Friday, September 13th. They now have an “overweight” rating on the stock. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Amarin Co. plc presently has a consensus rating of “Buy” and a consensus target price of $12.63.
Shares of Amarin Co. plc (NASDAQ:AMRN) traded up 1.11% during mid-day trading on Thursday, hitting $6.37. The stock had a trading volume of 7,752,865 shares. Amarin Co. plc has a 52 week low of $5.12 and a 52 week high of $12.96. The stock’s 50-day moving average is $6.56 and its 200-day moving average is $6.4. The company’s market cap is $1.100 billion. Amarin Co. plc also saw some unusual options trading activity on Monday. Stock traders purchased 24,205 call options on the company. This represents an increase of 183% compared to the typical daily volume of 8,556 call options.
Amarin Co. plc (NASDAQ:AMRN) last announced its earnings results on Thursday, August 8th. The company reported ($0.26) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.38) by $0.12. The company had revenue of $5.50 million for the quarter. Analysts expect that Amarin Co. plc will post $-1.37 EPS for the current fiscal year.
Amarin Corporation plc (NASDAQ:AMRN) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.